Humanigen Announces Proposed Public Offering of Five Million Shares of Common Stock
March 29 2021 - 4:11PM
Business Wire
Humanigen, Inc. (Nasdaq: HGEN)
(“Humanigen”), a clinical stage biopharmaceutical company focused
on preventing and treating an immune hyper-response called
“cytokine storm” with its lead drug candidate lenzilumabTM, today
announced that it has commenced an underwritten public offering
5,000,000 shares of its common stock. In connection with this
offering, Humanigen expects to grant the underwriters a 30-day
option to purchase up to an additional 750,000 shares of common
stock. The offering is subject to market and other conditions, and
there can be no assurance as to whether or when the offering may be
completed or as to the actual size or terms of the offering.
Jefferies, Credit Suisse and Cantor are acting as joint
book-running managers for the offering. Bryan, Garnier & Co. is
acting as European lead manager for the offering, Oppenheimer &
Co. is acting as lead manager for the offering and H.C. Wainwright
& Co., National Securities Corporation and Roth Capital
Partners are acting as co-managers for the offering.
Humanigen intends to use the net proceeds from the offering for
manufacturing and commercial preparation in the event of receipt of
an Emergency Use Authorization from the Food and Drug
Administration for lenzilumabTM in hospitalized COVID-19 patients,
as well as for working capital and other general corporate
purposes.
A registration statement relating to the securities being sold
in the offering has been declared effective by the Securities and
Exchange Commission (the “SEC”). The securities will be offered
only by means of a prospectus supplement and accompanying
prospectus forming a part of the effective registration statement.
A preliminary prospectus supplement relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC’s website located at www.sec.gov. Copies of
the preliminary prospectus supplement and the accompanying
prospectus relating to and describing the terms of the offering may
be obtained, when available, from Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by e-mail at prospectus_department@jefferies.com or
by telephone at (877) 821-7388; Credit Suisse Securities (USA) LLC,
Attention: Prospectus Department, 6933 Louis Stephens Drive,
Morrisville, North Carolina 27650, by email at
usa.prospectus@credit-suisse.com or by telephone at (800) 221-1037;
or Cantor Fitzgerald & Co., Attention: Capital Markets, 499
Park Ave., 6th Floor, New York, New York 10022, by e-mail at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of any securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Forward-Looking Statements
This release contains forward-looking statements.
Forward-looking statements reflect management’s current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct and you should be
aware that actual events or results may differ materially from
those contained in the forward-looking statements. Words such as
“will,” “expect,” “intend,” “plan,” “potential,” “possible,”
“goals,” “accelerate,” “continue,” and similar expressions identify
forward-looking statements. Examples of forward-looking statements
in this release include, without limitation, statements regarding
the consummation of the offering, the terms of the offering, the
satisfaction of customary closing conditions with respect to the
offering and the anticipated use of the net proceeds of the
offering. Forward-looking statements are subject to a number of
risks and uncertainties including, but not limited to, the various
risks and uncertainties described in the “Risk Factors” sections
and elsewhere in the Company's periodic and other filings with the
Securities and Exchange Commission. All forward-looking statements
are expressly qualified in their entirety by this cautionary
notice. You should not place undue reliance on any forward-looking
statements, which speak only as of the date of this release. We
undertake no obligation to revise or update any forward-looking
statements made in this press release to reflect events or
circumstances after the date hereof or to reflect new information
or the occurrence of unanticipated events, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210329005744/en/
Humanigen Media Grace Catlett RXMD Gcatlett@rxmedyn.com
516-318-8563 Humanigen Investors Alan Lada Solebury Trout
ALada@SoleburyTrout.com 617-221-8006
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Humanigen (NASDAQ:HGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024